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Abstract: 
 
PURPOSE: The Center for Medicare & Medicaid Innovation Oncology Care Model (OCM) 
requires documentation of a 13-point Institute of Medicine care management plan for Medicare 
patients. In addition, OCM includes evaluation of quality using key performance measures that 
align with the ASCO Quality Oncology Practice Initiative (QOPI). Both efforts are designed to 
improve patient-centered care and foster patients’ engagement in their care plan. METHODS: A 
multicenter quality improvement project was conducted to develop a strategy to meet the OCM 
treatment planning (TP) requirement (Plan), pilot clinician education coupled with use of 
electronic TP in early-stage breast cancer (Do), evaluate the impact of TP on QOPI measures 
(Study), and develop recommendations for future implementation (Act). RESULTS: Thirty-three 
clinical providers and 171 women with breast cancer were included. Improved performance on 
several QOPI measures was observed for the intervention group compared with the historical 
control group. CONCLUSION: Meeting the OCM TP requirement through incorporating a 
technology solution provided an opportunity for quality improvement and preparation for full-
scale TP within the OCM. TP delivery was associated with improved performance on select 
ASCO QOPI measures, which is likely to correspond with improved performance on quality 
measures within OCM. 
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QUESTION ASKED: Does implementation of treatment
plans (TPs) improve performance on ASCO Quality
Oncology Practice Initiative (QOPI) measures?
SUMMARY ANSWER: Implementation of electronic
TPs, which included patient-reported outcome (PRO)
data, improved performance on some ASCO QOPI
measures.
WHAT WE DID: We used a Plan-Do-Study-Act cycle to
conduct a multicenter quality improvement project
implementing TPs, which met Oncology Care Model
(OCM) requirements in patients with early-stage breast
cancer. We evaluated the impact of TPs on QOPI
measures and developed recommendations for future
implementation.
WHAT WE FOUND: This quality improvement project
engaged 33 clinical providers and 171 women with
breast cancer. We found improved performance on
several QOPI measures for the intervention group
compared with the historical control group. The mea-
sures with greatest change addressed management of
pain, emotional distress, and documentation of ad-
vanced directives.
BIAS, CONFOUNDING FACTORS, DRAWBACKS: This
study did not meet the desired accrual because one
site transitioned to standard-of-care TP delivery before
project completion. This specific TP intervention in-
cludes a PRO component; thus, it is difficult to assess
whether the PROs alone or within the TP drove im-
provement. In addition, we could not discern differ-
ences on the basis of documentation versus change in
practice. Finally, we did not collect data on use of TPs
at later encounters, so it is not possible to discern the
long-term impact.
REAL-LIFE IMPLICATIONS: This treatment planning
approach, which included PROs, was implemented
across three sites and improved select QOPI
measures. Given the OCM requirement for TPs, this
highlights the possibility to use OCM requirements
as an opportunity to improve quality of care
delivery.
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abstract
PURPOSE The Center for Medicare & Medicaid Innovation Oncology Care Model (OCM) requires documentation
of a 13-point Institute of Medicine care management plan for Medicare patients. In addition, OCM includes
evaluation of quality using key performance measures that align with the ASCO Quality Oncology Practice
Initiative (QOPI). Both efforts are designed to improve patient-centered care and foster patients’ engagement in
their care plan.
METHODS A multicenter quality improvement project was conducted to develop a strategy to meet the OCM
treatment planning (TP) requirement (Plan), pilot clinician education coupled with use of electronic TP in early-
stage breast cancer (Do), evaluate the impact of TP on QOPI measures (Study), and develop recommendations
for future implementation (Act).
RESULTS Thirty-three clinical providers and 171 women with breast cancer were included. Improved perfor-
mance on several QOPI measures was observed for the intervention group compared with the historical control
group.
CONCLUSION Meeting the OCM TP requirement through incorporating a technology solution provided an op-
portunity for quality improvement and preparation for full-scale TP within the OCM. TP delivery was associated
with improved performance on select ASCO QOPI measures, which is likely to correspond with improved
performance on quality measures within OCM.
J Oncol Pract 15:e271-e276. © 2019 by American Society of Clinical Oncology
INTRODUCTION
In 2011, the Institute of Medicine (IOM) called for all
patients with cancer to receive patient-centric treat-
ment planning (TP), including an IOM care man-
agement plan with the following 13 required
components: diagnosis; treatment; goals of ther-
apy; advanced care planning; expected course of
physical, practical, and psychosocial effects; and
resources for prevention and mitigation.1 In 2016,
the Center for Medicare & Medicaid Innovation
Oncology Care Model (OCM) required documen-
tation of IOM plans for Medicare beneficiaries. In
addition, OCM measures key performance in-
dicators, many of which align with the ASCO Quality
Oncology Practice Initiative (QOPI).2,3
In 2015, the University of Alabama at Birmingham
(UAB), University of South Alabama Mitchell Cancer
Institute (MCI), and AtlantiCare Cancer Care Institute
(ACCI) applied for participation in OCM. These three
cancer centers believed that leveraging the OCM re-
quirement of TP delivery would create an opportunity
to improve care quality. After evaluating their current
care practices and resources, the centers partnered
with Carevive Systems, a third-party technology solu-
tion that incorporates patient-reported outcomes
(PROs) into treatment and survivorship planning
documents. The centers hypothesized that provider
education coupled with electronic TP use for patients
with early-stage breast cancer would improve perfor-
mance on QOPI measures.3,4 This study evaluated the
goal of improving performance on QOPI quality metrics
through TP delivery using the Plan, Do, Study, Act
(PDSA) model.5
METHODS
Study Overview
This pre– and post–quality improvement project from
Fall 2015 through Spring 2016 used a PDSA cycle to
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evaluate the impact of provider education coupled with
electronic TP delivery on QOPI measure performance.
Institutional review boards at each participating cancer
center approved this study.
Participants
Providers. UAB and MCI are academic medical centers.
ACCI is a community hospital–based medical oncology
practice. Physicians, nurse practitioners, nurses, and other
clinical staff who delivered care for patients with breast
cancer were eligible to participate in provider education on
breast cancer treatment, supportive care, and quality
standards.
Patients. For the intervention group, women ages 18 and
older with stage I to III breast cancer were identified through
screening of clinic lists. Patients who had planned for or
were receiving chemotherapy treatment were approached
for participation at their first or second medical oncology
visit. Patients unable to speak English were excluded. In-
tervention patients provided informed consent. A historical
control group of consecutive patients with breast cancer
who received chemotherapy and who were treated before
initiation of TPs at each cancer center was identified using
medical record review. A waiver of consent was granted for
patients in the control group. The target accrual goal was 90
intervention and 90 control group patients across sites.
Intervention
This study used a two-part clinical intervention, which
combined a provider education intervention and patient TP
delivery. For the provider education component, providers
participated in an educational intervention of self-study,
continuing medical education (CME) courses on quality
standards relevant to human epidermal growth factor re-
ceptor 2–positive breast cancer and on psychosocial dis-
tress. These courses were chosen to highlight the need for
distress screening and enhancing familiarity with quality
improvement in addition to clinical updates in breast
cancer treatment. For the TP component, patients in the
intervention group completed the following electronic PRO
(ePRO) surveys on a tablet that connected to the TP
platform: family history, desire for future fertility, pain and
National Comprehensive Cancer Network distress as-
sessment, and Control Preferences Scale.6,7 The research
coordinator or nurse navigator abstracted clinical data el-
ements (eg, cancer stage, biomarkers, hormone receptor
status, age, date of diagnosis, and recommended treat-
ment) for each participant from the electronic medical
record (EMR) and then entered data into the TP platform.
The ePRO and clinical data elements were processed
through clinical algorithms to generate an evidence-based,
patient-facing TP designed to improve patient un-
derstanding of and engagement in their own care (example
TP shown in the Data Supplement). Participating providers
reviewed the TPs, chose to accept or reject TP recom-
mendations, and then finalized each TP. Hard copy TPs
were handed directly to all intervention patients during a
clinic visit. A copy of the TP also was sent electronically
through either e-mail or patient portal for reference.
Outcomes
Fifteen QOPI measures from within the core, symptom, and
breast modules were chosen for reporting because of their
alignment with OCM measures. Data were abstracted from
medical records and entered into the QOPI reporting
system using the standard QOPI process during QOPI Fall
2015 (UAB control), Spring 2016 (UAB intervention, MCI
control), and Fall 2016 (MCI intervention, ACCI intervention
and control) rounds.
Statistical Analysis
Descriptive statistics were used to examine characteristics
from the Carevive Systems platform. Continuous variables,
including age and time since initial cancer diagnosis, were
evaluated with means and standard deviations. Categorical
variables, including chemotherapy status, pathologic
staging, tumor pathology, and biomarker status, were
evaluated with frequencies and percentages. A full de-
scription of the study sample is listed in Table 1. Com-
parison of compliance rates between treatment and control
providers were evaluated using bivariate crosstabs with
condition as the independent variable and compliance as
the dependent variable, treating each QOPI variable in-
dependently. To account for reduced sample size on
specific items, Fisher’s exact test was used to evaluate
statistical significance.
RESULTS
Study Population
Of 85 women approached, 74 (87%) chose to participate in
the intervention (Table 1). Thirty-three providers and
clinical staff participated in the CME activities, including 15
nurses, 13 physicians, two nurse practitioners, one phar-
macist, and two other clinical practice staff. All providers
participated in the CME education. Records of 86 patients
from the historical control group also were abstracted.
Performance on Quality Measures
Table 2 lists the 15 selected QOPI measures for comparison
between intervention and control group patients. Statisti-
cally significant differences were found on nine measures,
with performance higher among those in the intervention
group. Responses to questions that pertained to man-
agement of pain, emotional distress, and documentation of
advanced directives had the greatest difference.
DISCUSSION
The cancer centers recognized the need to implement
structured TP (Plan), pilot TP delivery (Do), evaluate the
impact on quality measures (Study), and develop recom-
mendations for future TP delivery at participating cancer
centers (Act) as part of payment reform initiatives. Use of
e272 © 2019 by American Society of Clinical Oncology Volume 15, Issue 3
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electronic TPs coupled with targeted provider education
was associated with improved performance on select ASCO
QOPI measures. These metrics also align with OCM key
performance indicators linked to performance-based
payments.8 Performance improvements were greatest for
measures tied directly to ePROs or TP documentation,
which likely reflect a combination of improved documen-
tation, increased provider awareness of patient concerns, and
algorithm-based TP recommendations acted on by the patient
or clinical staff. In contrast, measures that required additional
intervention from a clinician (eg, presence of an advance
directive within the EMR or referrals for genetic testing)
showed only modest improvements. These findings com-
plement those of other studies on TPs in early-stage breast
cancer, where 90% to 94% of patients who received TPs
reported improved patient-physician communication.9,10
The three centers identified TP as a process rather than as
a static document. On completion of this PDSA cycle, all
have made substantial modifications to their TP process,
including use of a dashboard to present key PRO and
clinical recommendations and to integrate TPs into the
clinical workflow to improve patient-centered care quality.
Given the complexity and time-consuming effort of TP data
abstraction, UAB partnered with its EMR vendor, Cerner
(North Kansas City, MO) to interface with Carevive Systems
to improve efficiency. In addition, UAB assigned lay nav-
igators to initiate the ePROs, which provided a natural entry
point for navigation. Lay navigators reviewed ePRO re-
sponses and referred patients to appropriate resources,
including financial counseling, social work, psychology,
and palliative care. MCI’s and ACCI’s workflow differed
modestly, with nurse navigators (MCI) or research nurses
(ACCI) initiating ePRO surveys; entering clinical data di-
rectly into the Carevive Systems platform; building TPs; and
delivering TPs to provide in-depth, patient-specific edu-
cation and to set expectations for self-management and
care coordination with the patient. A scanned copy of the
TP was placed in the EMR and provided to the patient.
Electronic copies were provided on patient request. The
paper and electronic TPs allowed patients to share their TP
with other providers. All three centers believe that this
systematic integration of TP into routine caremaximized the
benefit for OCM participants of TP delivery, and they
currently are examining clinical (eg, reduced hospitaliza-
tions) and financial outcomes (ie, performance-based
payments) using data from their first OCM performance
period.
This quality improvement study had several limitations. The
study did not meet desired accrual because ACCI transi-
tioned from the research pilot to standard-of-care delivery
of TPs after 12 patients as a result of a later date of project
implementation. This highlights the challenge in pilot
testing to meet an urgent clinical need secondary to a policy
requirement. In contrast, UAB and MCI’s pilot was con-
ducted before OCM implementation, which was used to
demonstrate feasibility and guide subsequent imple-
mentation when OCM began. In addition, the quality im-
provement driver is not known because no manner existed
to discern differences on the basis of documentation versus
change in practice. We also did not test the PROs alone
versus within the TP, so these components cannot be
evaluated separately. Detailed demographic information
was collected only on the intervention patients in the
Carevive Systems platform; control group patients had data
on QOPI measures only. We did not collect data on the use
of TPs at later encounters, so it is not possible to discern
the long-term impact. However, OCM implementation is
TABLE 1. Patient Intervention Group Characteristics Taken From the
Carevive Systems Platform
Characteristic No. (%)
No. of patients 74
Mean age, years 55.4
Range 24-79
Standard deviation 11.2
Mean time since diagnosis, months 1.9
Range 0-21
Standard deviation 3.5
Chemotherapy status
Planned but not started 56 (76)
Currently receiving 9 (12)
None planned 7 (9)
Missing 2 (3)
Pathologic staging
I 19 (26)
II 34 (45)
III 19 (26)
Missing 2 (3)
Tumor pathology
Invasive ductal carcinoma 30 (40)
Invasive lobular carcinoma 6 (8)
Mixed ductal and lobular carcinoma in situ 3 (4)
Other pathology 5 (7)
Unknown at time of study 28 (38)
Missing 2 (3)
Biomarker status*
HR+ HER22 29 (39)
HR+ HER2+ 16 (21)
HR2 HER2+ 8 (11)
Triple negative (HR2, HER22) 18 (25)
Missing 3 (4)
Abbreviations: HER2, human epidermal growth factor receptor; HR,
hormone receptor.
*HR+ defined as either estrogen receptor or progesterone receptor
positive.
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ongoing, and future evaluation is planned, including the
impact of EMR integration that subsequently occurred at
two of three sites to support scalability of efforts. Finally, this
study evaluated short-term quality measures. More data are
needed to understand the impact of ePRO-directed TPs on
clinical and financial outcomes, especially given recent
findings of improved quality of life and survival with routine
PRO implementation.11
In conclusion, implementation of OCM TPs has provided an
opportunity to improve performance on quality measures.
Additional workflow optimization was needed to extend
beyond the pilot phase and to scale to full OCM imple-
mentation, which has been previously described.12 Ulti-
mately, the incorporation of technology solutions to meet
requirements for participation in payment reform initiatives
may provide a platform to effect patient outcomes.
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TABLE 2. Performance on Quality Measures Across Cancer Centers by Intervention Versus Control
Compliance, No. (%)
QOPI Item Intervention Group Control Group
Pain assessed by second office visit* 74 (100) 73 (85)
Pain intensity quantified by second office visit* 74 (100) 69 (95)
Plan of care for moderate/severe pain documented by second office visit* 10 (77) 4 (36)
Pain addressed appropriately by second office visit and during most recent office visits* 71 (96) 62 (72)
Pain assessed on either of the two most recent office visits 74 (100) 86 (98)
Pain intensity quantified on either of the two most recent office visits 74 (100) 82 (98)
Plan of care for moderate/severe pain documented on either of the two most
recent office visits
11 (79) 9 (47)
Pain addressed appropriately on either of the two most recent office visits* 71 (96) 72 (84)
Effectiveness of narcotic assessed on visit after prescription* 28 (100) 20 (80)
Constipation assessed at time of narcotic prescription or next visit 18 (62) 11 (44)
Chemotherapy intent (curative v non-curative) documented before or within 2 weeks after
administration
74 (100) 85 (99)
Chemotherapy intent discussion with patient documented 68 (97) 84 (98)
Patient emotional well-being assessed by second office visit* 64 (84) 61 (71)
Action taken to address problems with emotional well-being* 25 (93) 4 (17)
Documentation of patient's advance directives by the third office visit* 12 (63) 9 (17)
NOTE. Data were not collected on all QOPI items for all patients. A total of 74 patients were in the intervention group, and a total of 86 patients were in the
historical control group.
Abbreviation: QOPI, Quality Oncology Practice Initiative.
*Fisher’s exact test P , 0.05 (two-tailed)
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